

## Senior Vice President, Chief Medical Officer **David Kallend, MBBS**

---



David Kallend joined The Medicines Company in January of 2013 and has been Senior Vice President and Chief Medical Officer since March 2018. David has extensive experience in the pharmaceutical industry. Previously, David worked as an International Clinical Research Physician on imaging studies for Schering AG in Berlin, predominantly in magnetic resonance contrast media for liver, vascular and joint imaging. David joined AstraZeneca in July 1998, based in the United Kingdom, working mainly on the development of rosuvastatin from Phase II to Phase IV and the post-approval phase. From 2005 to 2012 he was the Global Clinical Leader and a Group Medical Director for dalcetrapib and other metabolism products at Roche. David has a MBBS from Kings College Hospital School of Medicine in London, United Kingdom.

---